Jascayd Effectiveness in Idiopathic Pulmonary Fibrosis
Jascayd (nerandomilast) 18 mg twice daily is effective at slowing lung function decline in adults with idiopathic pulmonary fibrosis, reducing FVC decline by approximately 69 mL compared to placebo at 52 weeks, and demonstrates a significant 43% reduction in mortality risk. 1, 2, 3
Lung Function Preservation
The FDA-approved dose of 18 mg twice daily demonstrated clear efficacy in the pivotal FIBRONEER-IPF trial involving 1,177 patients:
- FVC decline at 52 weeks: Patients on Jascayd 18 mg twice daily had an adjusted mean decline of -106 mL versus -170 mL with placebo, representing a treatment difference of 64 mL (95% CI: 25-102 mL, P<0.001) 1
- The more recent analysis showed an even larger treatment effect of 68.8 mL (95% CI: 30.3-107.4, P<0.001) 2
- This benefit was consistent across subgroups, including patients on background antifibrotic therapy (nintedanib or pirfenidone) and those not on antifibrotics 1
Important caveat: The 9 mg twice daily dose showed inferior efficacy and should not be used except in patients unable to tolerate the 18 mg dose (and never with concomitant pirfenidone due to lack of efficacy in that subgroup) 1.
Survival Benefit
While the composite endpoint of acute exacerbation, respiratory hospitalization, or death was not statistically significant in the primary analysis 4, pooled analyses demonstrate a robust mortality benefit:
- 43% reduction in death risk with 18 mg twice daily (HR: 0.57,95% CI: 0.41-0.78, P<0.001) when pooling IPF and PPF trial data 3
- In IPF alone, HR for death was 0.66 (95% CI: 0.41-1.08) over the full trial duration (mean 14.8 months) 4
- Sensitivity and tipping point analyses confirmed the robustness of this survival benefit, with very low likelihood that missing data explained the effect 3
- Exposure-response analyses showed higher plasma concentrations correlated with lower mortality risk, supporting the 18 mg twice daily dosing 3
Clinical Context and Positioning
The 2022 ATS/ERS/JRS/ALAT guidelines do not address nerandomilast (approved in 2025), but they establish that antifibrotic therapy is standard for IPF 5. Nerandomilast represents a mechanistically distinct option as a PDE4B inhibitor with both antifibrotic and immunomodulatory effects 2.
Key advantages:
- Can be used as monotherapy or with background antifibrotics (nintedanib or pirfenidone) 1
- 77.7% of trial patients were already on antifibrotics at enrollment, demonstrating real-world applicability 2
- Lower discontinuation rate (16.1% for 18 mg dose) compared to historical antifibrotic data 4
Safety Profile
The most common adverse event is diarrhea (41.3% vs 16.0% placebo), which is manageable and led to relatively low treatment discontinuation 2, 4:
- Other common events (≥5%): upper respiratory infections, depression, weight loss, decreased appetite, nausea, fatigue 1
- Serious adverse events were balanced across groups 2
- No dose reduction needed for renal or hepatic impairment in the FDA label 1
Critical drug interaction: Reduce dose to 9 mg twice daily with strong CYP3A inhibitors; avoid moderate/strong CYP3A inducers 1.
Practical Implementation
- Dosing: 18 mg orally twice daily, approximately 12 hours apart, with or without food 1
- Tablets: Can be swallowed whole or dispersed in water for patients with swallowing difficulty 1
- Monitoring: Standard IPF monitoring applies; no specific additional monitoring required beyond adverse event assessment
- Duration: Trial data support continued treatment beyond 52 weeks, with mean exposure of 14.8 months showing sustained benefit 4
The magnitude of FVC benefit (64-69 mL at 52 weeks) is clinically meaningful and comparable to established antifibrotics, while the mortality signal—though requiring confirmation in dedicated trials—represents a potentially practice-changing finding that prioritizes the most critical patient outcome.